Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma, for Whom Treatment With Ipilimumab is Indicated

NCT01810016 is registered in ClinicalTrials.gov with Ludwig Institute for Cancer Research as lead sponsor.

NCT NCT01810016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01810016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma, for Whom Treatment With Ipilimumab is Indicated
Lead sponsor
Ludwig Institute for Cancer Research
Phase
Phase 1
Overall status
Terminated
Start date
January 24, 2014
Completion date
May 17, 2016
Enrollment
8 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable or metastatic melanoma